In the present study, using the CRISPR/Cas9 system and ssODN, we attempted to introduce the T315I mutation into three Ph+ myeloid leukemia cell lines that showed resistance to olaparib (a PARP1 inhibitor). The gene discussed is PARP1; the disease is myeloid leukemia.